a Institute of Food Science and Engineering, School of Medical Instrument and Food Engineering , University of Shanghai for Science and Technology , Shanghai , China.
Biotechnol Genet Eng Rev. 2018 Oct;34(2):261-280. doi: 10.1080/02648725.2018.1506898. Epub 2018 Aug 10.
Hirudin was discovered as an active anticoagulant in leech extracts almost 60 years ago. Since their initial discovery, hirudin and its variants have been produced with various anti-thrombotic, cancer cell inhibition, diabetic cataract treatment and anti-fatigue activities. Some hirudin variants have been approved for clinical use and released into the marketplace. Recent progress has seen made in relation to hirudin variants expressed in several well-established microbial hosts, including Escherichia coli, Saccharomyces cerevisiae, Pichia pastoris and others, with high levels of activity and yield. This review summarizes the current progress on hirudin production using microbial producers, and considers the outlook for future development.
水蛭素作为一种具有活性的抗凝剂，在 60 年前从水蛭的提取物中被发现。自最初被发现以来，水蛭素及其变体已被广泛应用于抗血栓、抑制癌细胞、治疗糖尿病性白内障和抗疲劳等领域。部分水蛭素变体已获得临床批准并投放市场。近年来，在包括大肠杆菌、酿酒酵母、巴斯德毕赤酵母等在内的多种已建立的微生物宿主中表达的水蛭素变体取得了显著进展，这些变体具有高活性和高产量。本综述总结了利用微生物生产水蛭素的最新进展，并对未来的发展前景进行了探讨。
